News
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.
GlobalData on MSN1d
Wegovy becomes first GLP-1RA to gain FDA MASH approval
The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Health and Me on MSN17h
Wegovy Approved For MASH Treatment With Fibrosis But No Cirrhosis
FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...
The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback